These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24819707)

  • 1. Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).
    Hannon TS; Kirkman MS; Patel YR; Considine RV; Mather KJ
    Diabetes Metab Res Rev; 2014 Nov; 30(8):767-76. PubMed ID: 24819707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function.
    Patel YR; Kirkman MS; Considine RV; Hannon TS; Mather KJ
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4076-4084. PubMed ID: 27533307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.
    Kusunoki Y; Katsuno T; Myojin M; Miyakoshi K; Ikawa T; Matsuo T; Ochi F; Tokuda M; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
    Endocr J; 2013; 60(4):431-9. PubMed ID: 23220949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in β-cell function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes.
    Kahleova H; Mari A; Nofrate V; Matoulek M; Kazdova L; Hill M; Pelikanova T
    J Diabetes Complications; 2012; 26(5):442-9. PubMed ID: 22673566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool.
    Schnell O; Weng J; Sheu WH; Watada H; Kalra S; Soegondo S; Yamamoto N; Rathod R; Zhang C; Grzeszczak W
    J Diabetes Complications; 2016; 30(4):628-37. PubMed ID: 26935335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different clinical prognostic factors are associated with improved glycaemic control: findings from MARCH randomized trial.
    Han J; Yu H; Tu Y; Pang J; Liu F; Bao Y; Yang W; Jia W
    Diabet Med; 2017 Apr; 34(4):490-499. PubMed ID: 27151271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?
    van Raalte DH; Verchere CB
    Diabetes Obes Metab; 2017 Sep; 19(9):1205-1213. PubMed ID: 28295962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antioxidant N-Acetylcysteine does not improve glucose tolerance or β-cell function in type 2 diabetes.
    Szkudlinska MA; von Frankenberg AD; Utzschneider KM
    J Diabetes Complications; 2016; 30(4):618-22. PubMed ID: 26922582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI).
    Nijpels G; Boorsma W; Dekker JM; Kostense PJ; Bouter LM; Heine RJ
    Diabetes Metab Res Rev; 2008; 24(8):611-6. PubMed ID: 18756586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acarbose on insulin sensitivity in elderly patients with diabetes.
    Meneilly GS; Ryan EA; Radziuk J; Lau DC; Yale JF; Morais J; Chiasson JL; Rabasa-Lhoret R; Maheux P; Tessier D; Wolever T; Josse RG; Elahi D
    Diabetes Care; 2000 Aug; 23(8):1162-7. PubMed ID: 10937515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms.
    Astiarraga B; Gastaldelli A; Muscelli E; Baldi S; Camastra S; Mari A; Papadia F; Camerini G; Adami G; Scopinaro N; Ferrannini E
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2765-73. PubMed ID: 23666972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in glucose metabolism in people with different glucose metabolism disorders at baseline: follow-up results of a Finnish national diabetes prevention programme.
    Rautio N; Jokelainen J; Oksa H; Saaristo T; Peltonen M; Puolijoki H; Tuomilehto J; Vanhala M; Moilanen L; Uusitupa M; Keinänen-Kiukaanniemi S
    Diabet Med; 2015 Dec; 32(12):1611-6. PubMed ID: 25864699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
    Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired beta cell glucose sensitivity and whole-body insulin sensitivity as predictors of hyperglycaemia in non-diabetic subjects.
    Walker M; Mari A; Jayapaul MK; Bennett SM; Ferrannini E
    Diabetologia; 2005 Dec; 48(12):2470-6. PubMed ID: 16261308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
    Franz MJ; Boucher JL; Rutten-Ramos S; VanWormer JJ
    J Acad Nutr Diet; 2015 Sep; 115(9):1447-63. PubMed ID: 25935570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
    Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.